Suchergebnisse - "Thuresson, Per-Olof"

PubPharm (7)

1

A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma

enthalten in: Advances in therapy | 2020

von Thuresson, P. | Vander Velde, N. | Gupta, P. | +1

2

The societal impact of obinutuzumab in the first-line treatment of patients with follicular lymphoma in Germany

enthalten in: Journal of comparative effectiveness research | 2020

von Hofmann, S. | Himmler, S. | Ostwald, D. | +3

3

US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma

enthalten in: Journal of comparative effectiveness research | 2020

von Betts, K. | Thuresson, P. | Felizzi, F. | +5

ErratumIn: J Comp Eff Res. 2021 Mar;10(4):337. - PMID 33416405

4

Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States

enthalten in: Leukemia & lymphoma | 2019

von Guzauskas, G. | Masaquel, A. | Thuresson, P. | +2

5

Review of utility values for economic modeling in type 2 diabetes

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2014

von Beaudet, A. | Clegg, J. | Thuresson, P. | +2

6

Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden

enthalten in: Scandinavian journal of infectious diseases | 2011

von Thuresson, P. | Heeg, B. | Lescrauwaet, B. | +3

7

A pharmacoeconomic analysis of compliance gains on antipsychotic medications

enthalten in: Applied health economics and health policy | 2008

von Damen, J. | Thuresson, P. | Heeg, B. | +1

1
[1]